Shares in Insulet (NSDQ:PODD) rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results. The Billerica, Mass.-based company posted a net loss of -$7.8 million, or -13¢ per share, on sales of $109.8 million for the 3 months ended June 30, for bottom-line loss of -85% on […]
Insulet
Insulet, Ypsomed go their separate ways
Ypsomed has been the exclusive distributor of Insulet‘s (NSDQ:PODD) Omnipod insulin management system in Europe since 2010. But today, the companies announced that the arrangement is slated to end on June 30, 2018, after the pair could not agree on extending the contract based on the price set by Insulet, according to Ypsomed. Insulet said it will […]
Insulet, Mayo Clinic get in on Glooko’s $35m Series C round
Insulet (NSDQ:PODD) and Mayo Clinic were among the new investors to get in on a $35 million Series C round for Glooko and its diabetes management platform. The round was led by new investor Georgian Partners, joined by Insulet and Mayo Clinic and existing backers Medtronic, Samsung, Canaan Partners and Social Capital, Mountain View, Calif.-based Glooko said. The […]
Insulet asks court to force docs from Unilife in bankruptcy sale
A Delaware judge this week ordered formal submissions from both Unilife (NSDQ:UNIS) and Insulet (NSDQ:PODD) as the companies fought over Unilife’s Chapter 11 bankruptcy sale, with Insulet claiming Unilife is selectively refusing to supply appropriate information and restricting it’s ability to participate. Insulet claims that Unilife has not provided it with enough data to make an informed […]
Ascensia Diabetes Care inks integration deal with Insulet
Ascensia Diabetes Care said today it inked a strategic alliance with Insulet (NSDQ:PODD) to integrate connectivity between Insulet’s next-gen Omnipod system with Ascensia’s Contour Next One blood glucose monitoring system. Through the deal, Parsippany, N.J.-based Ascensia’s Contour Next will be designed to pair via Bluetooth with the Omnipod Dash personal diabetes manager to automatically communicate blood glucose […]
Insulet brings on new chief commercial exec | Personnel Moves – June 5, 2017
Insulet (NSDQ:PODD) last month named Bret Christensen as its chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy. He most recently served as GM of Myriad Genetics’ preventive care business division. He has also worked as VP of sales and marketing of the gynecologic surgical products unit at Hologic. Get […]
DJO Global names new surgical prez | Personnel Moves – June 1, 2017
DJO Global said this week that it hired Jeffery McCaully as global president of its surgical business, effectively immediately. McCaulley succeeded Brady Shirley, who was named DJO’s president & CEO in November last year. McCaulley previously served as president & CEO of Smiths Medical, as well as president of Zimmer Biomet‘s (NYSE:ZBH) global reconstructive unit, where […]
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at MassDevice’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent […]
Insulet Q1 misses on EPS, tops sales expectations
Shares in Insulet (NSDQ:PODD) have stayed steady in after hours trading today after the diabetes-focused medical device maker missed expectations on Wall Street with its 1st quarter losses per share, but topped sales expectations. The Billerica, Mass.-based company posted losses of $10 million, or 17¢ per share, on sales of $101.7 million for the 3 months […]
These big medtech names performed the best in early 2017
Fink Densford, Associate Editor and Chris Newmarker, Managing Editor This year so far has been an especially good one for medical device company stocks. More than four-fifths of the world’s 100 largest medical device companies saw their stock values increase during the first quarter of 2017 – about half enjoyed double-digit percentage increases, according to an analysis […]
Insulet slides on Q4 earnings miss
Insulet (NSDQ:PODD) shares are under pressure this morning after the diabetes company missed expectations for its 4th-quarter earnings, despite beating Wall Street’s consensus sales forecast. Billerica, Mass.-based Insulet narrowed its losses by -66.6%, to -$9.1 million, or -16¢ per share, on sales growth of 23.6% to $103.6 million for the 3 months ended Dec. 31, compared […]